美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Propanc Biopharma, Inc.

1.08

-0.0200-1.82%

盤後：1.080.00000.00%19:59 EDT

成交量：2.52萬

成交額：2.73萬

市值：246.06萬

市盈率：-0.03

高：1.12

開：1.12

低：1.05

收：1.10

52周最高：100.00

52周最低：0.9500

股本：227.84萬

流通股本：125.01萬

量比：0.71

換手率：2.02%

股息：- -

股息率：- -

每股收益(TTM):-32.4560

每股收益(LYR):-371.2241

淨資產收益率：-126.98%

總資產收益率：-62.31%

市淨率：0.25

市盈率(LYR):0.00

資料載入中...

總覽公司新聞資訊公告

Propanc Biopharma宣佈PRP在胰腺導管腺癌模型中展現超90%腫瘤生長抑制及顯著生存獲益的積極臨床前與早期轉化數據

Propanc Biopharma, Inc.將在澳大利亞提交CTA，啓動針對30-40名晚期癌症患者的1B期研究

Propanc Biopharma公司計劃開展兩項II期研究，針對胰腺癌和卵巢癌各招募60名患者

Propanc Biopharma實施並股計劃，以維繫納斯達克上市地位並推進增長戰略

Propanc Biopharma公司提交文件，計劃由售股股東轉售最多1500萬股普通股——SEC備案披露

Propanc Biopharma與西班牙哈恩大學及格拉納達大學達成多年抗衰老與癌症研究合作

Propanc Biopharma, Inc. 優先推進PRP臨床開發，聚焦胰腺癌與卵巢癌治療

Propanc Biopharma公司PRP藥物I B期首次人體試驗定於2026年啓動；1億美元資金設施已就位

Propanc Biopharma, Inc. 公布PRP在臨床前胰腺癌模型中展示超過85%的腫瘤生長抑制效果

Propanc Biopharma與Fyonibio簽署服務協議，為1B期首次人體研究建立並驗證藥代動力學分析方法

Propanc Biopharma主力資產PRP在臨床前胰腺癌模型中顯示超過85%的腫瘤生長抑制率

幣圈日報 | Circle財報：總收入和儲備金收入增長64%達27億美元；哈佛、布朗等大學捐贈基金開始配置比特幣ETF

幣圈日報｜Meta擬下半年重啓穩定幣項目；香港穩定幣支付公司RedotPay考慮年內赴美IPO

幣圈日報｜Coinbase託管美國超八成比特幣、以太坊ETF資產；SEC專員提議支付型穩定幣2%資本扣減

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/PPCB/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":1.08,"timestamp":1787342400000,"preClose":1.1,"halted":0,"volume":25211,"hourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.08,"latestTime":"19:59 EDT","volume":97,"amount":106.529,"timestamp":1787356770563,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.018181818181818195,"floatShares":1250069,"shares":2278372,"eps":-32.455997,"marketStatus":"休市中","change":-0.02,"latestTime":"08-21 16:00:00 EDT","open":1.12,"high":1.12,"low":1.05,"amount":27337.083967600003,"amplitude":0.063636,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-32.455997,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":1.1,"preHourTrading":{"tag":"盘前","latestPrice":1.16,"preClose":1.1,"latestTime":"09:26 EDT","volume":1145,"amount":1301.249906,"timestamp":1787318778928,"change":0.06,"changeRate":0.054545,"amplitude":0.054545},"postHourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.08,"latestTime":"19:59 EDT","volume":97,"amount":106.529,"timestamp":1787356770563,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7125297427585173},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":1250069,"roa":"-62.31%","roe":"-126.98%","lyrEps":-371.224075,"volumeRatio":0.7125297427585173,"shares":2278372,"dividePrice":0,"high":1.12,"amplitude":0.063636,"preClose":1.1,"low":1.05,"week52Low":0.95,"pbRate":"0.25","week52High":100,"institutionHeld":0,"latestPrice":1.08,"eps":-32.455997,"divideRate":0,"volume":25211,"delay":0,"ttmEps":-32.455997,"open":1.12,"prevYearClose":13.415,"prevWeekClose":1.22,"prevMonthClose":1.01,"prevQuarterClose":1.5,"fiveDayClose":1.22,"twentyDayClose":1.37,"sixtyDayClose":1.62},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-18","symbol":"PPCB","defaultRemindTime":1779111000000,"type":"split","dateTimestamp":1779076800000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-08-21","current":-0.033276,"percent":0.474708,"low":-1.336323,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"high":-0.023125,"avg":-0.183178,"sd":0.195775,"marketCap":2506208},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-30","current":-0.058573,"twenty":-0.449352,"median":-0.223866,"eighty":-0.121547,"marketCap":3713923},{"date":"2026-02-06","current":-0.042554,"twenty":-0.442879,"median":-0.192195,"eighty":-0.107345,"marketCap":2698240},{"date":"2026-02-13","current":-0.048688,"twenty":-0.435021,"median":-0.182701,"eighty":-0.093848,"marketCap":3087140},{"date":"2026-02-20","current":-0.048657,"twenty":-0.431486,"median":-0.176899,"eighty":-0.077306,"marketCap":3214676},{"date":"2026-02-27","current":-0.046857,"twenty":-0.428606,"median":-0.174834,"eighty":-0.060466,"marketCap":3095731},{"date":"2026-03-06","current":-0.040376,"twenty":-0.424799,"median":-0.173681,"eighty":-0.05647,"marketCap":2667530},{"date":"2026-03-13","current":-0.029045,"twenty":-0.422077,"median":-0.17085,"eighty":-0.050499,"marketCap":1918972},{"date":"2026-03-20","current":-0.028085,"twenty":-0.419765,"median":-0.170682,"eighty":-0.048484,"marketCap":1855535},{"date":"2026-03-27","current":-0.034166,"twenty":-0.417079,"median":-0.169454,"eighty":-0.047319,"marketCap":2257270},{"date":"2026-04-02","current":-0.035336,"twenty":-0.413827,"median":-0.167383,"eighty":-0.04606,"marketCap":2334602},{"date":"2026-04-10","current":-0.031762,"twenty":-0.406872,"median":-0.16427,"eighty":-0.043866,"marketCap":2098425},{"date":"2026-04-17","current":-0.033628,"twenty":-0.399911,"median":-0.155654,"eighty":-0.041322,"marketCap":2221738},{"date":"2026-04-24","current":-0.036697,"twenty":-0.399457,"median":-0.149858,"eighty":-0.040438,"marketCap":2424475},{"date":"2026-05-01","current":-0.032141,"twenty":-0.39557,"median":-0.138149,"eighty":-0.039889,"marketCap":2123505},{"date":"2026-05-08","current":-0.029421,"twenty":-0.386441,"median":-0.123469,"eighty":-0.037064,"marketCap":1943760},{"date":"2026-05-15","current":-0.023125,"twenty":-0.382964,"median":-0.117367,"eighty":-0.035899,"marketCap":1527837},{"date":"2026-05-22","current":-0.078772,"twenty":-0.376009,"median":-0.107725,"eighty":-0.036443,"marketCap":1446323},{"date":"2026-05-29","current":-0.077406,"twenty":-0.376009,"median":-0.101254,"eighty":-0.036697,"marketCap":1421242},{"date":"2026-06-05","current":-0.075584,"twenty":-0.369488,"median":-0.094421,"eighty":-0.037013,"marketCap":1387801},{"date":"2026-06-12","current":-0.110645,"twenty":-0.369488,"median":-0.091369,"eighty":-0.037013,"marketCap":2031540},{"date":"2026-06-18","current":-0.077861,"twenty":-0.359056,"median":-0.091369,"eighty":-0.037215,"marketCap":1429602},{"date":"2026-06-26","current":-0.068755,"twenty":-0.347754,"median":-0.088611,"eighty":-0.037494,"marketCap":1262397},{"date":"2026-07-02","current":-0.178687,"twenty":-0.344276,"median":-0.088611,"eighty":-0.038576,"marketCap":3280854},{"date":"2026-07-10","current":-0.220877,"twenty":-0.343407,"median":-0.091369,"eighty":-0.03962,"marketCap":4055500},{"date":"2026-07-17","current":-0.1973,"twenty":-0.335582,"median":-0.096459,"eighty":-0.039946,"marketCap":3622609},{"date":"2026-07-24","current":-0.179928,"twenty":-0.32515,"median":-0.101254,"eighty":-0.040156,"marketCap":3303637},{"date":"2026-07-31","current":-0.129051,"twenty":-0.321672,"median":-0.106776,"eighty":-0.040305,"marketCap":2369505},{"date":"2026-08-07","current":-0.16876,"twenty":-0.316456,"median":-0.111872,"eighty":-0.040388,"marketCap":3098584},{"date":"2026-08-14","current":-0.151387,"twenty":-0.306023,"median":-0.120497,"eighty":-0.04047,"marketCap":2779612},{"date":"2026-08-21","current":-0.136497,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"marketCap":2506208}],"updateTime":1787496120196},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1159793711","title":"Propanc Biopharma宣佈PRP在胰腺導管腺癌模型中展現超90%腫瘤生長抑制及顯著生存獲益的積極臨床前與早期轉化數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1159793711","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159793711?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 20:37","pubTimestamp":1786019874,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 近日公布了其核心候选药物PRP的积极临床前和早期转化研究结果。在胰腺导管腺癌（PDAC）模型中，PRP显示出超过90%的肿瘤生长抑制率，并显著延长了实验对象的生存期。这一里程碑式的数据，为后续的临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136433126","title":"Propanc Biopharma, Inc.將在澳大利亞提交CTA，啓動針對30-40名晚期癌症患者的1B期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1136433126","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136433126?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 20:46","pubTimestamp":1779281202,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 计划在澳大利亚提交临床试验申请，旨在启动一项涉及30至40名晚期癌症患者的1B期研究。这一举措标志着该公司在推进其新型癌症治疗方案的临床开发道路上迈出了关键一步。在澳大利亚提交CTA的决定，反映了公司利用该国高效监管框架和强大临床研究生态系统的战略考量。成功完成此阶段研究，有望为Propanc Biopharma, Inc.的核心产品管线带来重要的价值提升，并为其针对难治性癌症的开发策略提供关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186690041","title":"Propanc Biopharma公司計劃開展兩項II期研究，針對胰腺癌和卵巢癌各招募60名患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1186690041","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186690041?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 20:46","pubTimestamp":1779281199,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司宣布，将启动两项独立的II期临床研究，分别针对胰腺癌和卵巢癌患者。据悉，每项研究计划招募60名参与者，以评估其候选疗法的安全性与有效性。这一举措标志着该公司在推进其肿瘤治疗管线方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158942593","title":"Propanc Biopharma實施並股計劃，以維繫納斯達克上市地位並推進增長戰略","url":"https://stock-news.laohu8.com/highlight/detail?id=1158942593","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158942593?lang=zh_tw&edition=fundamental","pubTime":"2026-05-14 10:00","pubTimestamp":1778724015,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司已正式执行反向股票分割（并股）方案。此举旨在满足纳斯达克资本市场持续上市的最低股价要求，从而稳固其上市地位。同时，公司期望这一资本结构调整能为其既定的长期业务增长与拓展计划提供更坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118487671","title":"Propanc Biopharma公司提交文件，計劃由售股股東轉售最多1500萬股普通股——SEC備案披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1118487671","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118487671?lang=zh_tw&edition=fundamental","pubTime":"2026-04-11 05:33","pubTimestamp":1775856802,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司已向美国证券交易委员会提交相关文件，内容涉及一项由售股股东发起的普通股转售计划。根据备案信息，该计划拟转售的普通股数量最高可达1500万股。\n此次提交标志着售股股东可能将在公开市场进行大规模股份出售。相关细节已在SEC备案中列明，市场将密切关注此举对公司股权结构及二级市场股价的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193342077","title":"Propanc Biopharma與西班牙哈恩大學及格拉納達大學達成多年抗衰老與癌症研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1193342077","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193342077?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:46","pubTimestamp":1774356416,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. (OTC PINK: PPCB) 已正式启动与西班牙哈恩大学及格拉纳达大学的长期研究合作。该合作项目聚焦于抗衰老机制与癌症治疗领域的前沿探索，旨在通过多学科交叉研究推动新型生物医药解决方案的开发。此次合作将整合双方在生物医药领域的科研优势，共同探索潜在的新型疗法，为应对全球老龄化挑战及癌症治疗提供新的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169122345","title":"Propanc Biopharma, Inc. 優先推進PRP臨床開發，聚焦胰腺癌與卵巢癌治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1169122345","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169122345?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 21:07","pubTimestamp":1773320852,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 正全力推进其核心候选药物PRP的临床开发进程，并将胰腺癌与卵巢癌的治疗研究作为首要战略方向。公司致力于通过创新疗法应对这些高致死率癌症的临床挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142670016","title":"Propanc Biopharma公司PRP藥物I B期首次人體試驗定於2026年啓動；1億美元資金設施已就位","url":"https://stock-news.laohu8.com/highlight/detail?id=1142670016","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142670016?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 21:06","pubTimestamp":1773320789,"startTime":"0","endTime":"0","summary":"生物制药公司Propanc Biopharma Inc宣布，其主打候选药物PRP的I B期首次人体临床试验计划于2026年正式开展。该公司已确保一项高达1亿美元的资金支持，为临床试验的顺利推进提供了坚实的财务保障。\n此次I B期试验标志着PRP在研发进程中迈出关键一步，旨在评估该药物在人体中的安全性与初步疗效。充足的资金储备将助力公司高效执行临床开发计划，加速潜在疗法的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167918509","title":"Propanc Biopharma, Inc. 公布PRP在臨床前胰腺癌模型中展示超過85%的腫瘤生長抑制效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1167918509","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167918509?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 21:06","pubTimestamp":1773320779,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 近期宣布，其研发的主要候选药物PRP在针对胰腺癌的临床前研究中取得了显著成果。数据显示，PRP能够有效抑制肿瘤生长，抑制率超过85%。这一积极结果凸显了PRP在治疗胰腺癌方面的巨大潜力，为后续的临床开发提供了强有力的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192836728","title":"Propanc Biopharma與Fyonibio簽署服務協議，為1B期首次人體研究建立並驗證藥代動力學分析方法","url":"https://stock-news.laohu8.com/highlight/detail?id=1192836728","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192836728?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 20:45","pubTimestamp":1773146712,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 已正式与Fyonibio达成一项服务协议，核心目标是为其即将开展的1B期首次人体临床研究，建立并验证一套关键的药代动力学分析方法。该协议的签署标志着公司在推进其领先候选药物研发进程中迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170463595","title":"Propanc Biopharma主力資產PRP在臨床前胰腺癌模型中顯示超過85%的腫瘤生長抑制率","url":"https://stock-news.laohu8.com/highlight/detail?id=1170463595","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170463595?lang=zh_tw&edition=fundamental","pubTime":"2026-03-03 21:48","pubTimestamp":1772545721,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. (OTC: PPCB) 宣布，其领先研发资产PRP在针对胰腺癌的临床前研究模型中，展现出超过85%的肿瘤生长抑制效果。这一积极数据进一步验证了PRP作为潜在抗癌疗法的有效性，特别是在治疗胰腺癌这一难治性癌症领域显示出巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151214269","title":"幣圈日報 | Circle財報：總收入和儲備金收入增長64%達27億美元；哈佛、布朗等大學捐贈基金開始配置比特幣ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=1151214269","media":"老虎資訊","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151214269?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 11:13","pubTimestamp":1772075627,"startTime":"0","endTime":"0","summary":"Circle财报：总收入和储备金收入增长64%达27亿美元美股上市公司Circle发布2025财年业绩报告，其中披露截至2025年末的USDC流通量为753亿美元，增长72%；2025年第四季度USDC链上交易量为11.9万亿美元，增长247%；2025财年总收入和储备金收入为27亿美元，增长64%。哈佛、布朗等大学捐赠基金开始配置比特币ETF面对传统资产回报率预期下降，多家大学捐赠基金正在调整投资策略，开始配置加密货币 ETF。","market":"us","thumbnail":"https://static.tigerbbs.com/9712b6f035d7a01dae3855140d621802","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9712b6f035d7a01dae3855140d621802"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSK","COSM","01328","00165","BTBT","ARKB","EZBC","CAN","ATOM.USD.HKCC","BMNR","COMP.USD.CC","MARA","QETH","BRRR","ICG","BTC.USD.CC","AVAX.USD.CC","FBTC","IBIT","LINK.USD.CC","DOT.USD.CC","02598","DYDX.USD.HKCC","09959","COIN","ETHV","BTCO","09618","MATIC.USD.CC","MKR.USD.CC","SBET","SOS","ETHE","09923","EZET","EBON","ETHW","ETH","BTCT","LTC.USD.CC","FETH","HODL","ETH.USD.CC","SNX.USD.CC","02888","UNI.USD.CC","AAVE.USD.CC","NCTY","BTCM","BTCS","BITO","DEFI","BTM","PPCB","MSTR","ETHA","BTCW","RIOT","00863","BITB","06060","LDO.USD.HKCC","CETH","GBTC","OP.USD.HKCC","RNDR.USD.HKCC","USDT.USD.CC"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1177262629","title":"幣圈日報｜Meta擬下半年重啓穩定幣項目；香港穩定幣支付公司RedotPay考慮年內赴美IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1177262629","media":"老虎資訊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177262629?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 11:14","pubTimestamp":1771989265,"startTime":"0","endTime":"0","summary":"Meta计划2026年下半年重推稳定币项目据CoinDesk报道，知情人士透露，Facebook母公司Meta计划于2026年下半年重返稳定币领域，目前正寻求与第三方供应商合作以管理稳定币支付并实施新钱包功能。彭博社：香港稳定币支付公司RedotPay考虑最早于今年在美国IPO，融资额或超10亿美元据彭博社报道，总部位于香港的稳定币支付公司RedotPay正考虑在美国进行首次公开募股，潜在融资额超过10亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/9712b6f035d7a01dae3855140d621802","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9712b6f035d7a01dae3855140d621802"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ETHW","BTCS","BTCM","00165","BITB","ETHE","COMP.USD.CC","FETH","MSTR","MARA","NCTY","FBTC","OP.USD.HKCC","02598","USDT.USD.CC","IBIT","LINK.USD.CC","01328","BTCT","BTM","AVAX.USD.CC","ETHA","BTBT","02888","09618","MATIC.USD.CC","RIOT","UNI.USD.CC","HODL","MKR.USD.CC","ATOM.USD.HKCC","ARKB","BITO","DOT.USD.CC","LTC.USD.CC","PPCB","LDO.USD.HKCC","BTCO","09923","DEFI","SOS","ICG","CAN","09959","ETHV","CLSK","QETH","BRRR","COIN","SNX.USD.CC","COSM","RNDR.USD.HKCC","GBTC","SBET","EBON","00863","ETH.USD.CC","CETH","AAVE.USD.CC","DYDX.USD.HKCC","EZBC","BTC.USD.CC","06060","BTCW","EZET","ETH","BMNR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1114232543","title":"幣圈日報｜Coinbase託管美國超八成比特幣、以太坊ETF資產；SEC專員提議支付型穩定幣2%資本扣減","url":"https://stock-news.laohu8.com/highlight/detail?id=1114232543","media":"老虎資訊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114232543?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 11:20","pubTimestamp":1771903219,"startTime":"0","endTime":"0","summary":"Coinbase CEO：平台已托管超80%的美国比特币和以太坊ETF资产Coinbase首席执行官Brian Armstrong在X平台发文表示，Coinbase平台目前已托管超过80%的美国比特币与以太坊ETF资产，2025年录得ETF资金流入峰值达到310亿美元。Coinbase也是多家ETF发行方的指定托管合作伙伴，其中包括部分全球最大型金融机构及政府机构，并强调这是一项极其重要的责任。","market":"us","thumbnail":"https://static.tigerbbs.com/9712b6f035d7a01dae3855140d621802","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9712b6f035d7a01dae3855140d621802"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02598","COMP.USD.CC","ETH.USD.CC","BTM","BITO","EZET","MATIC.USD.CC","BTCM","09923","ETHW","NCTY","BMNR","USDT.USD.CC","AVAX.USD.CC","PPCB","BTCT","06060","RNDR.USD.HKCC","ETH","FETH","LINK.USD.CC","BTC.USD.CC","OP.USD.HKCC","MKR.USD.CC","ETHE","GBTC","CLSK","COIN","UNI.USD.CC","MSTR","QETH","CETH","ETHA","BITB","CAN","ETHV","BTBT","09618","BTCO","SBET","BTCS","09959","DYDX.USD.HKCC","02888","01328","BRRR","EZBC","RIOT","DEFI","DOT.USD.CC","ICG","ATOM.USD.HKCC","00863","BTCW","HODL","LTC.USD.CC","MARA","AAVE.USD.CC","LDO.USD.HKCC","COSM","SNX.USD.CC","00165","SOS","ARKB","EBON","IBIT","FBTC"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}